LPS-123 is a covalently irreversible BTK inhibitor with an IC50 of AKT/mTOR and MAPK signaling pathways, activation of PLCgamma2, ERK1/2, p38, AKT, and mTOR, and blocks the production of CCL3 and CCL4 chemokines. LPS-123 exhibits significant anti-proliferative activity against various B-cell lymphoma cell lines and effectively induces apoptosis via a caspase-dependent pathway. LPS-123 also demonstrates significant antitumor activity in the OCI-Ly7 xenograft model. LPS-123 can be used for lymphoma research[1].
Molecular Weight:
617.58
CAS Number:
[1431727-04-6]
Formula:
C31H26F3N7O4
Target:
Akt,Apoptosis,Btk,CCR,ERK,mTOR,p38 MAPK
Application Notes:
MCE Product type: Reference compound1
* VAT and and shipping costs not included. Errors and price changes excepted
